BackLatigo Biotherapeutics Overview

Latigo Biotherapeutics EBIT

Track Latigo Biotherapeutics's EBIT ($-110M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$20.25M

As of Sep 30, 2026

Annual EBIT (TTM)

-$108.04M

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Latigo Biotherapeutics (LTGO) FAQ

Latigo Biotherapeutics (LTGO) currently reports a EBIT of $-110M as of September 2026. That is below the sector sector average of $2.4T. Use the charts on this page to explore Latigo Biotherapeutics's EBIT history and peer comparisons.

Latigo Biotherapeutics's EBIT of $-110M is lower than the its sector sector average of $2.4T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Latigo Biotherapeutics reported $-110M in EBIT as of September 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-110M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.4T. From there, open related valuation or income-statement pages for Latigo Biotherapeutics, and consider following LTGO for alerts when major investors trade the stock.